Female aging: when translational models don't translate

For many pathologies associated with aging, female patients present with higher morbidity and more frequent adverse events from treatments compared to male patients. While preclinical models are the foundation of our mechanistic understanding of age-related diseases, the most common models fail to recapitulate archetypical female aging trajectories. For example, while over 70% of the top age-related diseases are influenced by the systemic effects of reproductive senescence, we found that preclinical studies that include menopausal phenotypes modeling those seen in humans make up <1% of published aging biology research. The long-term impacts of pregnancy, birthing and breastfeeding are also typically omitted from preclinical work. In this Perspective, we summarize limitations in the most commonly used aging models, and we provide recommendations for better incorporating menopause, pregnancy and other considerations of sex in vivo and in vitro. Lastly, we outline action items for aging biology researchers, journals, funding agencies and animal providers to address this gap.

Automated summary

Female patients have higher morbidity and more frequent adverse events from treatments compared to males in many age-related diseases. However, the commonly used preclinical models fail to replicate typical female aging trajectories and lack research on menopause, pregnancy, and other gender considerations. Therefore, it is necessary for aging biology researchers, journals, funding agencies, and animal providers to take action to address this gap.